|
KMID : 1030220190200030149
|
|
Journal of Korean Diabetes
2019 Volume.20 No. 3 p.149 ~ p.156
|
|
|
Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
|
|
Lee In-Kuk
Kang Eun-Seok
|
|
|
Abstract
|
|
|
|
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
|
|
|
KEYWORD
|
|
|
Cardiovascular diseases, Diabetes mellitus, Glucagon-like peptide-1, Kidney diseases, Obesity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|